Connect with BÜHLMANN at UEGW 2022
The broadest fecal calprotectin portfolio from lab to patient,
and the exclusive offer of the complete rapid TDM for biologics
and its antibodies on Quantum Blue®
Calprotectin in IBD Diagnosis and Monitoring
Inflammatory Bowel Disease (IBD) includes Crohn’s Disease (CD) and Ulcerative Colitis (UC), two currently incurable serious chronic diseases of the intestinal tract. IBD symptoms strongly resemble those of non-inflammatory diseases such as irritable bowel syndrome (IBS). Fecal calprotectin has proven itself as an excellent surrogate marker in IBD diagnosis and helps to reliably select patients for further invasive diagnostic procedures. Further, calprotectin in stool can also be used for disease monitoring in diagnosed patients since it correlates closely with mucosal healing. High calprotectin values are indicative for active inflammation in the gut, while moderate fecal calprotectin values can represent mild organic disease. In addition to fecal calprotectin, the monitoring of biologics trough levels (TDM) as part of the therapeutic follow-up in IBD patients is becoming standard care. Taken all this together, BÜHLMANN offers the broadest product portfolio supporting decision making in the IBD treatment management. Further, BÜHLMANN is the only company offering biologic trough level measuring as well as anti-biologic antibody testing as rapid tests.
BÜHLMANN Highlights at UEGW 2022
New IBDoc® Calprotectin Home Test Tutorial Video
IBDoc® is a home testing device for the quantitative determination of fecal calprotectin. Three easy steps allow for remote monitoring of calprotectin levels in IBD patients at their home. By using IBDoc® health care professionals can directly monitor patient results.
New CALEX® Cap Stool Collection Set Tutorial Video
The CALEX® Cap Collection Set allows for home stool collection at patients home. Using the CALEX® Cap extraction device, both fecal calprotectin and pancreatic elastase can be measured out of the same extraction tube. The CALEX® Cap Collection Set is fully compatible with the BÜHLMANN fecal calprotectin and p-elastase assays.
New IBDoc® Success Story
Prof. Patrick van Rheenen, a renowned pediatrician working at the University Medical Center Groningen (UMCG) in the Netherlands, talked about the successful integration of the IBDoc® fecal calprotectin home test into a hospital remote monitoring system, using the standard HL7 communication pathway.
New Quantum Blue® TDM Success Story
In an interview, Dr. Giuliana Cangemi from the Gaslini Institute of the Pediatric Hospital in Genova, Italy, explains how they successfully introduced all four Quantum Blue® TDM assays into clinical routine.
BÜHLMANN Poster Highlights at UEGW 2022
BÜHLMANN Quantum Blue® fPELA
- P0843, J. Afonso et al., Switzerland
BÜHLMANN Quantum Blue® Capillary Blood Assays for TDM
- P0354, L. Brosi et al., Switzerland
BÜHLMANN Calprotectin Assays and TDM Testing
BÜHLMANN is the gold standard for IBD diagnosis and monitoring offering the largest product portfolio of calprotectin testing and TDM rapid tests for biologics in IBD. The product portfolio includes the FDA cleared BÜHLMANN fCAL® turbo for high throughput testing. The immuno turbidimetric fecal calprotectin assay BÜHLMANN fCAL® turbo provides flexible and random access applications on all major clinical chemistry platforms. The assay allows short turnaround time from fecal sample to the reportable result. The combination of the test with the CALEX® Cap extraction device or the fecal home extraction kit CALEX® Cap Collection Set strongly simplifies the cumbersome procedure for stool pre-analytics and is adapted to be applied on clinical chemistry analysers. BÜHLMANN also offers the FDA cleared market leader BÜHLMANN fCAL® ELISA and the Quantum Blue® calprotectin rapid tests. Further to that, the portfolio includes IBDoc®, a highly successful IBD home test for patients using an app that transforms smartphones into a calprotectin test reading device.
The BÜHLMANN Quantum Blue® rapid test combines the ease and speed of lateral flow technology, with full quantification by means of a small reading device. The Quantum Blue® Reader provides a quantitative value within minutes and is therefore an ideal tool in a point-of-care setting. The BÜHLMANN product line offers two different fecal calprotectin test ranges suitable for IBD diagnosis and therapy follow-up of IBD patients. Besides calprotectin assays, BÜHLMANN offers the possibility for TDM for biologics in IBD on the Quantum Blue® Reader.
IBDoc® is the first in vitro diagnostic home testing device measuring the inflammatory marker fecal calprotectin at home. The IBDoc® mobile app turns your smartphone into a test cassette reader using state of the art image processing. Stool extraction is performed using the CALEX® Valve that is characterized by its simple and convenient handling of stool samples. The secure data connection between the IBDoc® mobile app and the IBDoc® Portal allows Health Care Professionals to directly monitor patient results. The IBDoc® Portal also includes an application programming interface (api) that directly transfers test results into electronic patient records (EHR) or laboratory information systems (LIMS) via a common web standard or HL7 based interface.
The CALEX® Cap Collection Set places this device to patients home, further reducing the laboratory task of stool extraction procedure for fecal calprotectin and pancreatic elastase testing with BÜHLMANN assays. The CALEX® Cap extraction device offers efficient, convenient and hygienic direct home stool collection.
BÜHLMANN CALEX® Cap extraction device offers efficient, convenient and hygienic stool extraction. Its simple design and buffer offers the user high safety as well as high stability of stool samples. Furthermore, the CALEX® Cap is designed to be fully compatible with TLA solutions.
The new assay BÜHLMANN fPELA® turbo and the well-established BÜHLMANN fCAL® turbo together with the CALEX® Cap have revolutionized fecal testing. Both turbidimetric immunoassays can be easily applied for a wide choice of clinical chemistry analysers, providing TLA with fast turn-around-time (TAT) and improve laboratory workflow. The combined use of these products make reliable results possible for an extended measuring range.
BÜHLMANN has launched its first assay for fecal calprotectin testing more than 15 years ago and is today considered as the gold standard with the BÜHLMANN fCAL® ELISA. Two protocols are available with the BÜHLMANN fCAL® ELISA to cover different calprotectin ranges for IBD diagnosis and monitoring.